产品
编 号：F711984
分子式：C23H30Cl2N2O2
分子量：437.4
分子式：C23H30Cl2N2O2
分子量：437.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1902123-72-1
产品详情
生物活性：
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity.
体内研究：
GSK2879552 dihydrochloride (1.5 mg/kg，po) 处理在携带 SCLC 异种移植物的小鼠中表现出肿瘤生长抑制。Animal Model:NCI-H526 and NCI-H1417 xenografts.
Dosage:1.5 mg/kg.
Administration:PO daily for 25-35 days.
Result:There was 57% and 83% tumor growth inhibition (TGI) in NCI-H526 and NCI-H1417 tumor bearing mice respectively. NCI-H510 and NCI-H69 tumor bearing mice also demonstrated partial TGI (38% and 49% respectively) in response to GSK2879552, while no significant TGI was observed for SHP77 bearing mice.
体外研究：
GSK2879552 dihydrochloride 抑制 KDM1A 组蛋白去甲基化酶活性，诱导索拉非尼耐药细胞的分化并减弱干细胞特性。GSK2879552 dihydrochloride 在索拉非尼耐药细胞中抑制 Wnt 拮抗剂的转录并下调 β-catenin 信号活性。
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity.
体内研究：
GSK2879552 dihydrochloride (1.5 mg/kg，po) 处理在携带 SCLC 异种移植物的小鼠中表现出肿瘤生长抑制。Animal Model:NCI-H526 and NCI-H1417 xenografts.
Dosage:1.5 mg/kg.
Administration:PO daily for 25-35 days.
Result:There was 57% and 83% tumor growth inhibition (TGI) in NCI-H526 and NCI-H1417 tumor bearing mice respectively. NCI-H510 and NCI-H69 tumor bearing mice also demonstrated partial TGI (38% and 49% respectively) in response to GSK2879552, while no significant TGI was observed for SHP77 bearing mice.
体外研究：
GSK2879552 dihydrochloride 抑制 KDM1A 组蛋白去甲基化酶活性，诱导索拉非尼耐药细胞的分化并减弱干细胞特性。GSK2879552 dihydrochloride 在索拉非尼耐药细胞中抑制 Wnt 拮抗剂的转录并下调 β-catenin 信号活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备